News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Pfizer Inc. (PFE) Lung Cancer Drug Doubles Benefit, Researchers Say


10/1/2012 7:36:35 AM

Pfizer Inc. (PFE)’s lung-cancer medicine Xalkori extended the lives of patients without their disease worsening for twice as long as the standard therapies, according to a study sponsored by the New York-based drugmaker. In a trial of 347 previously treated patients whose non- small lung cancer showed mutations in the gene known as ALK, those given Pfizer’s Xalkori experienced progression-free survival to 7.7 months, compared with 3 months for patients on the other treatments, according to results presented today at the European Society for Medical Oncology in Vienna.

Read at BusinessWeek


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES